Trial Profile
A Double Blind, Randomized, Repeat-Dose, Parallel Group Study to Define the ECG Effects of Lixivaptan Using a Clinical and a Supratherapeutic Dose, Compared to Placebo and Moxifloxacin (a Positive Control), in Healthy Adult Men and Women: A Thorough ECG Study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Jun 2015
Price :
$35
*
At a glance
- Drugs Lixivaptan (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Cardiokine
- 03 Jun 2015 New trial record